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Opinion statement
House dust mite (HDM) allergen exposure is the most important cause of perennial allergic
rhinitis and/or asthma. Although allergen-specific immunotherapy (AIT) with HDM is well
established, published studies have been characterized by substantial heterogeneity in
clinical endpoints. Standardization in measuring clinical efficacy is required. Moreover, when
designing an AIT trial with HDM allergens, several considerations have to be taken into
account. The history of HDM allergy is less clear cut than the typical history of pollen allergy.
In addition, clinical features of HDM allergy may differ from those of pollen allergy. Moreover,
although not easily measurable, fluctuation in allergen exposure may cause variation in
symptom severity and determine the timing of assessment of clinical effects of HDM AIT.
Key points
1. A combined symptom and medication score (CSMS) is recommended as standard for the
primary endpoint in future house dust mite (HDM) allergen-specific immunotherapy trials.
2. The diagnosis of HDM allergy is based on a carefully taken history in combination with
sensitization to HDM allergens.
3. Eye symptoms are less prominent in patients with HDM-induced allergic rhinitis. Nasal
symptoms, but not eye symptoms, should be included in the CSMS and in symptom scores
as well.
4. As methods to determine allergen exposure vary and the efficacy of environmental control
is a matter of debate, a practical approach consists of restraining patients from
implementing HDM-reducing measures, such as removing carpets and introducing anti-
mite covers, after the start of the study.
5. Efficacy evaluation in the period with the highest exposure to mites is recommended.
Introduction
One of the most relevant groups of indoor allergens in
causing perennial allergic rhinitis (AR) and/or allergic
asthma (AA) is found in the bodies and feces of house
dust mites (HDM), with the two main species being
Dermatophagoides pteronyssinus and Dermatophagoides
farinae [1, 2, 3••]. Besides allergen avoidance as a (sec-
ondary or tertiary) preventive treatment, which often
lacks sufficient efficacy in domestic settings [4], the treat-
ment of mite allergy is mainly based on antiallergic
pharmacotherapy, as well as on allergen-specific immu-
notherapy (AIT) [3••, 5•, 6]. In a position paper on AIT,
the World Health Organization (WHO) clearly
highlighted the clinical efficacy of AIT in patients with
HDM-induced AR and AA [7]. Within the last two de-
cades, an increasing number ofmeta-analyses have dem-
onstrated clear evidence of the clinical efficacy of this
treatment for both subcutaneous and sublingual AIT
(SCIT and SLIT) in HDM allergy [3••, 8–10]. However,
in a recently published systematic evidence-based review
on the clinical efficacy of HDM AIT, the authors empha-
sized “marked inter study heterogeneity in terms of
primary and secondary efficacy criteria” [3••]. One
reason for this heterogeneity can be seen in specific
considerations of HDM-induced allergic diseases that
differentiate them from (pollen-induced) seasonal AR
and AA.
Various clinical endpoints in published AIT trials for
allergic rhinoconjunctivitis (ARC) were recently
reviewed in a current position paper from the European
Academy of Allergy and Clinical Immunology (EAACI)
[11••].
This article aims to (1) review examples of dif-
ferent outcome measures (primary and secondary),
as published in the literature on HDM AIT trials
(as grouped into seven domains); and (2) discuss
general limitations and special considerations for
clinical trials in this indication (in contrast to AIT
trials in seasonal allergies). The latter include dif-
ferences in the diagnosis of AR, the clinical charac-
teristics of patients with AR due to HDM allergy,
and clinical manifestations of the disease; and lim-
itations in measuring the allergen exposure of the
patients, as well as the problem of the timing of
clinical assessment of HDM AIT.
Outcome measures in house dust mite allergen-specific
immunotherapy trials
Symptom scores
For AR, scoring of symptoms has been determined as clinical endpoint in several
HDMAIT trials, both for the subcutaneous route (e.g., see references [12–14]) and
for the sublingual route (e.g., see references [15–17]). However, there is a high
grade of heterogeneity in the definition of the respective SS throughout the
literature. Moreover, in some study protocols, composite-scores with nose- and
lung-symptoms were used whereas a few also included conjunctival symptoms
(reviewed in [3••]).One recently published trial of sublingualmite-allergen tablets
used the Average Adjusted Symptom Score (AAdSS) as a primary endpoint [18•].
The EAACI position paper on clinical outcomes of AIT trials for ARC [11••]
recommends a daily symptom score (dSS) in perennial AR caused byHDM, based
on four nasal symptoms, as follows: itchy nose, sneezing, runny nose, and blocked
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nose, on a scale of 0–3 points (modified from references [19, 20]). Conjunctival
symptoms are not included in this recommended scoring of the primary endpoint
in AIT trials in HDM-allergic patients [11••] (see also discussion under “General
limitations and special considerations for clinical trials in this indication”).
(Asthma) SS have also been used as a clinical endpoint parameter in several
clinical trials of HDM AIT (e.g., see references [21–24], reviewed in reference
[3••]). As for AR, differences in asthma SS are found in comparison of these
trials, with a lack of harmonized standardization of this endpoint. In the light of
the need for comparability of the efficacy of HDM AIT, an international stan-
dard for the definitions of asthma SS to be used as clinical endpoints would be
preferable in future trials.
Medication scores
In some clinical trials of HDM AIT in AR patients, medication scores (MS) have
been used as clinical endpoints (e.g., [13, 15, 18]). As for SS, no definite
standard (for both the specific class of pharmacotherapy to be administered as
concomitant medication and their scoring for the MS) has been used. The
EAACI position paper recommends a stepwise use of antiallergic medication
and gives a standardized definition for the daily medication score (dMS)
[11••], which is in line with, and is modified from, the World Allergy Organi-
zation (WAO) recommendations [19].
Some AIT trials in asthma patients have also used MS as clinical endpoints
(e.g., see references [25–28]). Again, heterogeneous use of medication and
scoring systems is found in the respective trial protocols, with some of them
being related to andmodified from a standard published by Dreborg et al. [29].
Combined symptom and medication scores
In AR, one AIT trial on HDM-allergic adult patients [30] has used a combined
symptom andmedication score (clinical index score [CIS]) as primary endpoint.
In principle, combining symptom scores and medication scores in a composite
single score as primary clinical endpoint in AIT trials is in line with the European
Medicine Agency (EMA) “Guideline on the Clinical Development of Products for
Specific Immunotherapy for the Treatment of Allergic Diseases” [20]. However,
there is still a lack of thorough global standardization.
The EAACI position paper highlights for the primary endpoint in future AIT-
trials a homogeneous combined symptom and medication score (CSMS) as a
simple and standardized method. This score balances both symptoms and the
impact of antiallergic medication in an equally weighted ratio [11••].
In AIT trials in HDM-induced AA, composite asthma symptom and asthma
medication scores have not been used as primary endpoints (reviewed in refer-
ence [3••]). However, in this indication, other endpoints such as controllability
of asthma may be preferred as primary outcomes (see “Control of the disease”).
Control of the disease
As an important alternative to measurements of disease severity (as analyzed, for
example, by SS), disease-specific “control” outcome questionnaires have recently
been developed and partly validated—e.g., the Control of Allergic Rhinitis and
Asthma Test (CARAT) [31•] and the Rhinitis Control Assessment Test (RCAT)
[32]. However, the scores from these questionnaires have not been used as clinical
endpoints in AIT trials in HDM-induced AR.
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However, in a recently published double-blind, placebo-controlled trial of
SLIT in patients with HDM-induced AA, well-controlled asthma (WCA), as
defined by the Global Initiative for Asthma (GINA; latest revision 2012 [33]),
was used as a primary endpoint by Wang et al. [28]. Another example is a
randomized, controlled trial in children with HDM-induced AA, which inves-
tigated the steroid-sparing effect of SCIT to maintain asthma control [34].
Quality of life
Quality-of-life (QoL) questionnaires were validated more than 20 years ago for
both AR [35] and AA [36] in different age groups. Furthermore, a questionnaire
evaluating both AR and AA in a composite format has been developed (see
reference [37], reviewed in reference [11••]). On this basis, QoL has been
evaluated in different AIT trials in HDM-induced AR [30] and AA [28].
Allergen challenge tests
Nasal provocation (NP; e.g., see references [38–40]) or conjunctival provoca-
tion (CP; e.g., see reference [30]) have been performed in different trials in
HDM-induced AR, whereas bronchial provocation (BP) has been performed in
trials in HDM-induced AA (e.g., see references [13, 25, 26]) for analyses of
secondary outcome endpoints (reviewed in reference [3••]). However, the
different challenge test methods have not been thoroughly standardized and
validated, which should be urgently addressed in the future, not only for their
clinical implications in HDM-AIT-trials (see details in reference [11••]). Envi-
ronmental challenge chambers may become promising candidates for allergen
provocation if thorough technical and clinical validation can be realized [41].
Well days
In the EMA “Guideline on the Clinical Development of Products for Specific
Immunotherapy for The Treatment of Allergic Diseases” [20], “days with symp-
tom control” with daily symptom scores below a “clinically justified level” are
recommended as secondary endpoints for the analysis of clinical efficacy in AIT
trials. As an example, one pediatric trial of SLIT in HDM-allergic children with
AR used “well days” and “symptom-free days” as secondary endpoints [42].
However, it is questionable if this definition initially developed for intermittent
(pollen-induced) AR can be extrapolated to persistent (HDM-induced) allergy.
General limitations and special considerations for clinical trials
in this indication
Diagnosis of allergic rhinitis based on house dust mite allergy
The clinical relevance of a history matching HDM allergy is less easy to establish
than the typical history of pollen allergy. Therefore, it has been suggested that a
positive allergen challenge test should be part of the inclusion criteria for HDM
trials [3••]. One problem might be that allergen challenge tests are not stan-
dardized. Moreover, the inclusion of nasal challenge tests has been used in a large
trial assessing the efficacy ofmattress covers [43] in children and adults withHDM
allergy, but a subanalysis showed that a positive HDM challenge test did not
4 Allergic Rhinitis (M Calderon, Section Editor)
substantially change the physician’s diagnosis based on symptoms and sensiti-
zation to HDM [44]. Therefore, a carefully taken history in combination with
sensitization to HDMallergens should be sufficient for establishing the diagnosis.
Clinical characteristics of patients with allergic rhinitis due to house dust mite allergy and the
clinical manifestation of the disease
It is generally believed that rhinitis due toHDM allergy is more characterized by
nasal obstruction than pollen allergy. Most AIT trials have reported the mean of
different nasal symptom category scores, without showing separate nasal SS. In
one small SLIT study inHDM-allergic children, low and comparable scores were
reported for sneezing, nasal blockage, nasal itching and rhinorrhea [45]. In a
study assessing the efficacy of montelukast and antihistamines, patients with
HDM allergy reported all nasal symptom categories. Higher scores for obstruc-
tion than for sneezing and itching were reported [46]. In another SLIT study in
children, rhinorrhea was seen in 89.4 % and nasal obstruction in 82.3 % of
patients [47]. In a large study assessing QoL in patients with intermittent and
persistent rhinitis, all nasal symptom categories were reported in themajority of
patients with persistent rhinitis [48]. Therefore, the use of composite nasal
scores is also justified in patients with HDM allergy.
Allergic conjunctivitis is often underestimated [49] and may have an impor-
tant impact on QoL, even more than nasal obstruction [50]. However, in a
subanalysis of children included in a retrospective HDM SLIT study, the fre-
quency of nasal symptoms ranged from 89.4 % for rhinorrhea to 61.7 % for
nasal pruritus, whereas the frequencies of ocular pruritus and teary eyes
amounted to only 25.7 % and 17.9 %, respectively [47]. In another HDM SLIT
study, eye scores were low [42]. In line with this, many randomized, controlled
AIT trials have measured only nasal symptoms without taking eye symptoms
into account [12–16, 51, 39, 40, 52–55], and fewer studies have included eye
symptoms in the assessment of efficacy [18•, 42, 45, 56–59].
The recent EAACI position paper on outcome measures in AIT trials advo-
cates the inclusion of eye scores in trials in rhinoconjunctivitis [11••]. Low eye
scores included in composite nasal/eye scores or combined symptom combi-
nation scores may, however, influence the effect size of treatment. For that
reason, focusing only on nasal symptoms inHDM trialsmay be justified [11••].
One has to bear in mind that the well-known Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ) has been validated for allergic rhinoconjunctivitis
[35]. Juniper et al. have also validated an instrument for perennial rhinitis [60].
Limitations in measuring allergen exposure of patients
In a few studies, measurement of HDM allergens has been performed. Exposure
can be measured at baseline. In one study, relatively low levels of the major
D. farinae allergenDer f 1were found in the settled dust samples. The levels ranged
from non-detectable to 8 µg/g of dust. Mean Der f 1 levels were similar in the
active treatment and placebo groups [51]. Exposuremay bemonitored during the
study. In two studies, no change in exposure could be observed [13, 14]. In
another study, HDM exposure was expressed in guanine levels in mattresses [53].
After 24 months, the number of patients with class 2±3 guanine levels decreased
significantly in both groups (P=0.01), while there was a concomitant increase in
the number of patients with low guanine levels (class 1), indicating a marked
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change in the indoor allergen load [53]. Such a decrease in Der p 1 was also
observed in a trial in asthmatics [55]. The latter study included help from an
environmental consultant and the introduction of anti-mitemattresses and pillow
covers before the start of the study. Although measurement and monitoring of
mite allergens for HDM AIT trials have been advocated [3••], one might argue
about the added value. Theoretically, a change in allergen exposure during treat-
ment may interfere with the results of AIT. As methods to determine allergen
exposure vary and the efficacy of environmental control is a matter of
debate [4], a more practical approach consists of restraining patients from
implementing HDM-reducing measures, such as removing carpets and
introducing anti-mite covers after the start of the study.
Timing of assessment of clinical effects of allergen-specific immunotherapy for house dust
mite allergy
Although peak HDM exposures are not as substantial as those seen in pollen
allergy, HDM exposure might be relatively high in autumn [61]. In a Polish AIT
study, differences relative to placebo were particularly evident in successive
heating seasons, which corresponds to the highest period of HDM allergen
exposure in Poland [56]. Also, in an Italian study, it was shown that rhinitis and
medication scores were significantly lower in the AIT group than in the placebo
group in October, November, and December [57]. Lower SS in the AIT group
than in the placebo group in most of the winter months (P=0.05) were
observed in another Italian study [59]. In one study, the diary had to be filled in
from November to February, when the exposure to indoor mites is expected to
be greater [58]. Also, other studies have taken a specific period of inclusion or
efficacy analysis into account [18•, 40, 42, 52, 53, 55]. Therefore, efficacy
evaluation in the period with the highest exposure to mites is recommended.
Moreover, assessment should always be done at yearly intervals and not at 6-
month intervals [16] or 18-month intervals [14, 55].
Compliance with Ethics Guidelines
Conflict of Interest
O. Pfaar (OP) has received research grants for his institution from ALK-Abelló (Germany/Denmark),
Allergopharma (Germany), Stallergenes (Germany/France), HAL Allergy (Germany/the Netherlands), Artu
Biologicals (the Netherlands), Allergy Therapeutics/Bencard (UK/Germany), Hartington (Spain), Lofarma
(Italy), Novartis/Leti (Germany/Spain), GlaxoSmithKline (UK/Germany), Essex Pharma (Germany), Cytos
(Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circas-
sia (UK), European Union (FP-7-Health-2013 Innovation 1), Biotech Tools s.a. (Belgium), and Meda Pharma
GmbH (Germany); and/or he has served as an advisor and on speakers’ bureaus for some of the aforemen-
tioned companies. OP has received travel grants from HAL Allergy (the Netherlands/Germany) and
Allergopharma (Germany), and he is a consultant for Bencard (Germany), HAL Allergy (the Netherlands),
Novartis/Leti (Germany), Meda (Germany), ALK-Abelló (Germany/Denmark) , Allergopharma (Germany),
Biotech Tools s.a. (Belgium), GfK Bridgehead (UK), Navigant Consulting (USA), Sanofi (USA), Guidepoint
Global Advisors (USA), Thermo Fisher (Germany) and Stallergenes (Germany/France); he is Scientific Board
Member of Mobile Chamber Experts (MCX), a GA2LEN Partner. OP is the current chairman Immunotherapy
6 Allergic Rhinitis (M Calderon, Section Editor)
Interest Group (IT IG) of the European Academy of Allergy and Clinical Immunology (EAACI) and is the
secretary of the ENT section of Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI).
He has received grants for the ‘‘Spezifische Immuntherapie’’-award 2014 and the ‘‘Nachwuchsförderpreis’’-
award 2010 of the DGAKI. He is co-editor and an author of the textbook "Allergien bei Kindern und
Jugendlichen" (publisher: Schattauer-Verlag, Germany) and author of different chapters of "Allergologie-
Handbuch" (publisher: Schattauer-Verlag, Germany) and has received payment for development of educa-
tional presentations from GlaxoSmithKline (Germany), Bencard (Germany), and Novartis (Germany).
R. Gerth van Wijk (RGW) has received fees for consultancy for MSD, HAL, Novartis, and Crucell. He has
received research grants from NWO, STW, Novartis, Biomay, DBV, and ALK. He has received payment for
lectures from Allergopharma, payment for manuscript preparation from Chiesi, and royalties from De
Tijdstroom and Bohn Stafleu van Loghum.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Mosbech H. House dust mite allergy. Allergy.
1985;40(2):81–91.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic
rhinitis and its impact on asthma. J Allergy Clin
Immunol. 2001;108(5 Suppl):S147–334.
3.•• Calderon MA, Casale TB, Nelson HS, Demoly P. An
evidence-based analysis of house dust mite allergen
immunotherapy: a call for more rigorous clinical stud-
ies. J Allergy Clin Immunol. 2013;132D6]:1322–36.
Recently published comprehensive analysis of different SCIT
and SLIT trials of HDM AIT in both HDM-induced AR and
HDM-induced AA. The focus of this analysis was on study
designs, doses, regimens, patient-reported outcomes, safety
reporting, and compliance. One central finding was the high
grade of heterogeneity of the endpoints used in these trials.
4. Custovic A, Wijk RG. The effectiveness of measures to
change the indoor environment in the treatment of
allergic rhinitis and asthma: ARIA update (in collabo-
ration with GA(2)LEN). Allergy. 2005;60(9):1112–5.
5.• Nelson HS. Update on house dust mite immunother-
apy: are more studies needed? Curr Opin Allergy Clin
Immunol. 2014;14D6]:542–8.
Overview of current trials of HDM-AIT—the US/American
view.
6. Calderon MA, Demoly P, Gerth van Wijk R, et al.
EAACI: a European declaration on immunotherapy.
Designing the future of allergen specific immunother-
apy. Clin Transl Allergy. 2012;2(1):20.
7. Bousquet J, Lockey R, Malling HJ. Allergen immuno-
therapy: therapeutic vaccines for allergic diseases. A
WHO position paper. J Allergy Clin Immunol.
1998;102(4 Pt 1):558–62.
8. Abramson MJ, Puy RM, Weiner JM. Injection allergen
immunotherapy for asthma. Cochrane Database Syst
Rev. 2010;8, CD001186.
9. Compalati E, Passalacqua G, Bonini M, Canonica GW.
The efficacy of sublingual immunotherapy for house
dust mites respiratory allergy: results of a GA2LEN
meta-analysis. Allergy. 2009;64(11):1570–9.
10. Eifan AO, Calderon MA, Durham SR. Allergen immu-
notherapy for house dust mite: clinical efficacy and
immunological mechanisms in allergic rhinitis and
asthma. Expert Opin Biol Ther. 2013;13(11):1543–56.
11.•• Pfaar O, Demoly P, Gerth van Wijk R, et al. Recom-
mendations for the standardization of clinical out-
comes used in allergen immunotherapy trials for aller-
gic rhinoconjunctivitis: an EAACI position paper. Al-
lergy. 2014;69D7]:854–67.
Position paper of the EAACI on clinical endpoints in AIT trials.
This position paper is structured into nine “domains” of dif-
ferent outcomes and highlights the advantages, disadvantages,
and specific recommendations on each parameter. As its main
achievement, the position paper recommends a homogeneous
CSMS as a simple and standardized method to be used as the
primary endpoint for future randomized, controlled trials of
AIT for allergic rhinoconjunctivitis.
12. Varney VA, Tabbah K, Mavroleon G, Frew AJ.
Usefulness of specific immunotherapy in patients
with severe perennial allergic rhinitis induced by
house dust mite: a double-blind, randomized,
placebo-controlled trial. Clin Exp Allergy.
2003;33(8):1076–82.
13. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU,
Karakoc GB. Effect of one-year subcutaneous and
Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy Pfaar and Gerth van Wijk 7
sublingual immunotherapy on clinical and laboratory
parameters in children with rhinitis and asthma: a
randomized, placebo-controlled, double-blind,
double-dummy study. Int Arch Allergy Immunol.
2012;157(3):288–98.
14. Pichler CE, Marquardsen A, Sparholt S, et al.
Specific immunotherapy with Dermatophagoides
pteronyssinus and D. farinae results in decreased
bronchial hyperreactivity. Allergy.
1997;52(3):274–83.
15. O'Hehir RE, Gardner LM, de LeonMP, et al. House dust
mite sublingual immunotherapy: the role for
transforming growth factor-beta and functional regu-
latory T cells. Am J Respir Crit Care Med.
2009;180(10):936–47.
16. Tseng SH, Fu LS, Nong BR, Weng JD, Shyur SD.
Changes in serum specific IgG4 and IgG4/IgE ratio in
mite-sensitized Taiwanese children with allergic rhini-
tis receiving short-term sublingual-swallow immuno-
therapy: a multicenter, randomized, placebo-
controlled trial. Asian Pac J Allergy Immunol.
2008;26(2–3):105–12.
17. Tonnel AB, Scherpereel A, Douay B, et al.: Allergic
rhinitis due to house dust mites: evaluation of the
efficacy of specific sublingual immunotherapy. Allergy
2004;59:491–7.
18.• Bergmann KC, Demoly P, Worm M, et al. Efficacy and
safety of sublingual tablets of house dust mite allergen
extracts in adults with allergic rhinitis. J Allergy Clin
Immunol. 2014;133D6]:1608–14.
Well-performed phase II/III study to assess the efficacy and
safety of two doses of HDM sublingual tablets over one treat-
ment year and the subsequent immunotherapy-free year in
509 randomized adult patients.
19. Canonica GW, Baena-Cagnani CE, Bousquet J, et al.
Recommendations for standardization of clinical trials
with allergen specific immunotherapy for respiratory
allergy. A statement of a World Allergy Organization
(WAO) taskforce. Allergy. 2007;62(3):317–24.
20. EuropeanMedicines Agency. Committee for Medicinal
Products for Human Use (CHMP). Guideline on the
Clinical Development of Products for Specific Immu-
notherapy for The Treatment of Allergic Diseases. Lon-
don: European Medicines Agency; 2008.
21. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM.
Regione Veneto Study Group on the "Effect of
Immunotherapy in Allergic Asthma”. Effect of
specific immunotherapy added to pharmacologic
treatment and allergen avoidance in asthmatic
patients allergic to house dust mite. J Allergy Clin
Immunol. 2004;113(4):643–9.
22. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-
year, placebo-controlled, double-blind house-dust-
mite immunotherapy study in asthmatic adults. Aller-
gy. 1997;52(8):853–9.
23. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY.
Efficacy of sublingual immunotherapy with high-
dose mite extracts in asthma: a multi-center,
double-blind, randomized, and placebo-controlled
study in Taiwan. Respir Med. 2006;100(8):1374–
83.
24. Ippoliti F, De Santis W, Volterrani A, et al.
Immunomodulation during sublingual therapy in al-
lergic children. Pediatr Allergy Immunol 2003;14:216–
21.
25. Ameal A, Vega-Chicote JM, Fernandez S, et al. Double-
blind and placebo-controlled study to assess efficacy
and safety of a modified allergen extract of
Dermatophagoides pteronyssinus in allergic asthma. Al-
lergy. 2005;60(9):1178–83.
26. Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-
Caldas E, Casanovas M. Successful management of
mite-allergic asthma with modified extracts of
Dermatophagoides pteronyssinus and Dermatophagoides
farinae in a double-blind, placebo-controlled study. J
Allergy Clin Immunol. 2006;118(5):1026–32.
27. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical
and immunologic effects of long-term sublingual im-
munotherapy in asthmatic children sensitized tomites:
a double-blind, placebo-controlled study. Allergy.
2000;55(9):842–9.
28. Wang L, Yin J, Fadel R, Montagut A, de Beaumont O,
Devillier P. House dust mite sublingual immunother-
apy is safe and appears to be effective in moderate,
persistent asthma. Allergy. 2014;69(9):1181–8.
29. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko
A, Nilsson S. A double-blind, multicenter immuno-
therapy trial in children, using a purified and stan-
dardized Cladosporium herbarum preparation. I Clinical
results Allergy. 1986;41(2):131–40.
30. Riechelmann H, Schmutzhard J, van der Werf JF, Distler
A, Kleinjans HA. Efficacy and safety of a glutaraldehyde-
modified house dust mite extract in allergic rhinitis. Am
J Rhinol Allergy. 2010;24(5):e104–9.
31.• Fonseca JA, Nogueira-Silva L, Morais-Almeida M, et al.
Control of Allergic Rhinitis and Asthma Test DCARAT]
can be used to assess individual patients over time. Clin
Transl Allergy. 2012;2D1]:16.
Report on recently developed disease-specific AR “control”
questionnaires, which may become useful candidates for
Dclinical] endpoints in future AIT trials.
32. Nathan RA, Dalal AA, Stanford RH, et al. Qualitative
development of the Rhinitis Control Assessment Test
(RCAT), an instrument for evaluating rhinitis symptom
control. Patient. 2010;3(2):91–9.
33. Global Initiative for Asthma (GINA). Global strategy
for asthma management and prevention. December
2012 update of the NHLBI/WHO Workshop Report
1995. Available from: http://www.ginasthma.org/.
2012.
34. Zielen S, Kardos P, Madonini E. Steroid-sparing effects
with allergen-specific immunotherapy in children with
asthma: a randomized controlled trial. J Allergy Clin
Immunol. 2010;126(5):942–9.
35. Juniper EF, Guyatt GH. Development and testing of a
new measure of health status for clinical trials in
rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–
83.
8 Allergic Rhinitis (M Calderon, Section Editor)
36. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke
R, Hiller TK. Evaluation of impairment of health relat-
ed quality of life in asthma: development of a ques-
tionnaire for use in clinical trials. Thorax.
1992;47(2):76–83.
37. Baiardini I, Pasquali M, Giardini A, et al. Rhinasthma: a
new specific QoL questionnaire for patients with rhi-
nitis and asthma. Allergy. 2003;58(4):289–94.
38. Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E.
Clinical effects of specific immunotherapy: a two-year
double-blind, placebo-controlled study with a one year
follow-up. Prilozi. 2005;26(2):113–29.
39. Gabriel MS, Ng HK, Allan WG, Hill LE, Nunn AJ.
Study of prolonged hyposensitization with D.
pteronyssinus extract in allergic rhinitis. Clin Al-
lergy. 1977;7(4):325–39.
40. Blainey AD, Philips MJ, Ollier RJ, Davies RJ. Hyposen-
sitization with a tyrosine adsorbed extract of
Dermatophagoides pteronyssinus in adults with perennial
rhinitis. Allergy. 1984;39:521–8.
41. Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environ-
mental exposure chambers in allergen immunotherapy
trials: current status and clinical validation needs (in
press). J Allergy Clin Immunol 2014; doi: 10.1016/
j.jaci.2014.10.045.
42. de Bot CM, Moed H, Berger MY, et al. Sublingual
immunotherapy not effective in house dust mite-
allergic children in primary care. Pediatr Allergy
Immunol. 2012;23(2):150–8.
43. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of
impermeable covers for bedding in patients with al-
lergic rhinitis. N Engl J Med. 2003;349(3):237–46.
44. Terreehorst I, Oosting AJ, Tempels-Pavlica Z, et al.
Prevalence and severity of allergic rhinitis in house dust
mite-allergic patients with bronchial asthma or atopic
dermatitis. Clin Exp Allergy. 2002;32(8):1160–5.
45. Aydogan M, Eifan AO, Keles S, et al. Sublingual im-
munotherapy in children with allergic
rhinoconjunctivitis mono-sensitized to house-dust-
mites: a double-blind-placebo-controlled randomised
trial. Respir Med. 2013;107(9):1322–9.
46. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski
P. Montelukast with desloratadine or levocetirizine for
the treatment of persistent allergic rhinitis. Ann Allergy
Asthma Immunol. 2006;97(5):664–71.
47. Trebuchon F, Lheritier-BarrandM,DavidM, Demoly P.
Characteristics andmanagement of sublingual allergen
immunotherapy in children with allergic rhinitis and
asthma induced by house dust mite allergens. Clin
Transl Allergy. 2014;4:15.
48. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and
impairment of allergic rhinitis in patients consulting in
primary care. J Allergy Clin Immunol.
2006;117(1):158–62.
49. Klossek JM, Annesi-Maesano I, Pribil C, Didier A. The
burden associated with ocular symptoms in allergic
rhinitis. Int Arch Allergy Immunol. 2012;158(4):411–7.
50. Bousquet PJ, Demoly P, Devillier P, Mesbah K,
Bousquet J. Impact of allergic rhinitis symptoms on
quality of life in primary care. Int Arch Allergy
Immunol. 2013;160(4):393–400.
51. Bush RK, Swenson C, Fahlberg B, et al. House
dust mite sublingual immunotherapy: results of a
US trial. J Allergy Clin Immunol.
2011;127(4):974–81. e1-7.
52. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy
of sublingual immunotherapy in children with asthma
and rhinitis: a double-blind, placebo-controlled study.
Pediatr Pulmonol. 2001;32(1):49–55.
53. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite
sublingual-swallow immunotherapy (SLIT) in peren-
nial rhinitis: a double-blind, placebo-controlled study.
Allergy. 2000;55(4):369–75.
54. Mungan D, Misirligil Z, Gurbuz L. Comparison of the
efficacy of subcutaneous and sublingual immunother-
apy in mite-sensitive patients with rhinitis and
asthma—a placebo controlled study. Ann Allergy
Asthma Immunol. 1999;82(5):485–90.
55. Pham-Thi N, Scheinmann P, Fadel R, Combebias A,
Andre C. Assessment of sublingual immunotherapy
efficacy in children with house dust mite-induced al-
lergic asthma optimally controlled by pharmacologic
treatment and mite-avoidance measures. Pediatr Aller-
gy Immunol. 2007;18(1):47–57.
56. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House
dust mite sublingual immunotherapy: a double-
blind, placebo-controlled study in elderly patients
with allergic rhinitis. Clin Exp Allergy.
2013;43(2):242–8.
57. Marcucci F, Sensi L, Di Cara G, et al. Three-year follow-
up of clinical and inflammation parameters in children
monosensitized to mites undergoing sub-lingual im-
munotherapy. Pediatr Allergy Immunol.
2005;16(6):519–26.
58. Passalacqua G, Pasquali M, Ariano R, et al. Random-
ized double-blind controlled study with sublingual
carbamylated allergoid immunotherapy in mild rhini-
tis due to mites. Allergy. 2006;61(7):849–54.
59. Passalacqua G, Albano M, Fregonese L, et al.
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in mite-
induced rhinoconjunctivitis. Lancet.
1998;351(9103):629–32.
60. Juniper EF, Guyatt GH, Andersson B, Ferrie PJ.
Comparison of powder and aerosolized
budesonide in perennial rhinitis: validation of
rhinitis quality of life questionnaire. Ann Allergy.
1993;70(3):225–30.
61. van der Heide S, de Monchy JG, de Vries K, Bruggink
TM, Kauffman HF. Seasonal variation in airway
hyperresponsiveness and natural exposure to house
dust mite allergens in patients with asthma. J Allergy
Clin Immunol. 1994;93(2):470–5.
Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy Pfaar and Gerth van Wijk 9
